Literature DB >> 1372592

Expression and function of membrane attack complex inhibitory proteins on thyroid follicular cells.

N Tandon1, B P Morgan, A P Weetman.   

Abstract

Human thyroid cells are resistant to lysis by the homologous membrane attack complex. By immunohistochemical staining we here show that normal thyroid cells and those in Graves' disease and Hashimoto's thyroiditis express two membrane attack complex-inhibiting proteins, CD59 antigen and membrane attack complex-inhibiting protein/homologous restriction factor (MIP/HRF). In vitro, the expression of both molecules was enhanced by interleukin-1 (IL-1), tumour necrosis factor (TNF) and interferon-gamma (IFN-gamma) and cytokine-treated thyroid cells were more resistant to lysis by homologous complement. Blocking experiments with monoclonal antibodies against CD59 antigen and MIP/HRF showed that both molecules contributed but CD59 antigen was the more important in mediating resistance to complement attack. Expression of these proteins may be an important determinant of the severity of tissue injury produced by complement-fixing thyroid peroxidase antibodies in autoimmune thyroid disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372592      PMCID: PMC1384722     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

1.  Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents.

Authors:  L C Wood; S H Ingbar
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

2.  Thyroid follicular cell function after non-lethal complement membrane attack.

Authors:  A P Weetman; M Freeman; B P Morgan
Journal:  Clin Exp Immunol       Date:  1990-10       Impact factor: 4.330

3.  Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.

Authors:  S Meri; B P Morgan; A Davies; R H Daniels; M G Olavesen; H Waldmann; P J Lachmann
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

4.  Expression of HRF20, a regulatory molecule of complement activation, on peripheral blood mononuclear cells.

Authors:  T Hideshima; N Okada; H Okada
Journal:  Immunology       Date:  1990-03       Impact factor: 7.397

5.  The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.

Authors:  S A Rollins; P J Sims
Journal:  J Immunol       Date:  1990-05-01       Impact factor: 5.422

6.  Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo.

Authors:  M Nose; M Katoh; N Okada; M Kyogoku; H Okada
Journal:  Immunology       Date:  1990-06       Impact factor: 7.397

7.  Protection of human amniotic epithelial cells (HAEC) from complement-mediated lysis: expression on the cells of three complement inhibitory membrane proteins.

Authors:  I A Rooney; B P Morgan
Journal:  Immunology       Date:  1990-11       Impact factor: 7.397

8.  Isolation and characterization of a membrane-attack-complex-inhibiting protein present in human serum and other biological fluids.

Authors:  M J Watts; J R Dankert; E P Morgan
Journal:  Biochem J       Date:  1990-01-15       Impact factor: 3.857

9.  Functional analysis of intercellular adhesion molecule-1-expressing human thyroid cells.

Authors:  A P Weetman; M Freeman; L K Borysiewicz; M W Makgoba
Journal:  Eur J Immunol       Date:  1990-02       Impact factor: 5.532

10.  The thyroid "microsomal" antibody revisited. Its paradoxical binding in vivo to the apical surface of the follicular epithelium.

Authors:  E L Khoury; G F Bottazzo; I M Roitt
Journal:  J Exp Med       Date:  1984-02-01       Impact factor: 14.307

View more
  9 in total

Review 1.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 2.  Membrane proteins that protect against complement lysis.

Authors:  B P Morgan; S Meri
Journal:  Springer Semin Immunopathol       Date:  1994

3.  Self-reactive B cells are not eliminated or inactivated by autoantigen expressed on thyroid epithelial cells.

Authors:  S Akkaraju; K Canaan; C C Goodnow
Journal:  J Exp Med       Date:  1997-12-15       Impact factor: 14.307

Review 4.  Association of Blood Group Antigen CD59 with Disease.

Authors:  Christof Weinstock
Journal:  Transfus Med Hemother       Date:  2022-01-13       Impact factor: 3.747

5.  Thyroid peroxidase autoantibodies are associated with a lesser likelihood of late reversion to hyperthyroidism after successful non-ablative treatment of Graves' disease in Croatian patients.

Authors:  M Stefanic; I Karner
Journal:  J Endocrinol Invest       Date:  2014-01-08       Impact factor: 4.256

6.  Expression and function of multiple regulators of complement activation in autoimmune thyroid disease.

Authors:  N Tandon; S L Yan; B P Morgan; A P Weetman
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

7.  Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor.

Authors:  A B Zaltzman; C W Van den Berg; V R Muzykantov; B P Morgan
Journal:  Biochem J       Date:  1995-05-01       Impact factor: 3.857

8.  Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium.

Authors:  K Koretz; S Brüderlein; C Henne; P Möller
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

9.  A bead-assisted flow cytometry method for the semi-quantitative analysis of Extracellular Vesicles.

Authors:  Henar Suárez; Ana Gámez-Valero; Raquel Reyes; Soraya López-Martín; María Josefa Rodríguez; José L Carrascosa; Carlos Cabañas; Francesc E Borràs; María Yáñez-Mó
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.